TITLE

Clinic Roundup

PUB. DATE
December 2010
SOURCE
BioWorld Today;12/8/2010, Vol. 21 Issue 236, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on clinical trials. A Phase III contraceptive trial for Savvy was completed by Adamis Pharmaceuticals Corp. Enrollment was initiated by BioMimetic Therapeutics Inc. in a trial of the Augment Rotator Cuff Graft for the repair of rotator cuff tears. Authorization was given by Swissmeci to StemCells Inc. to start Phase I/II trials of purified human neural stem cells for chronic spinal cord injury.
ACCESSION #
55698727

 

Related Articles

  • FDA Approves Trial of Adamis Pharmaceuticals Product Candidate to Treat Prostate Cancer.  // Biomedical Market Newsletter;6/9/2011, p84 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of Adamis Pharmaceuticals Corp.'s investigational new drug (IND) application for its APC-100 prostate cancer (PCa) treatment. It states that the company plans to start its Phase 1/2a clinical studies of APC-100 in...

  • Clinic Roundup.  // BioWorld Today;3/10/2011, Vol. 22 Issue 47, p2 

    This section offers news briefs related to biotechnology firms as of March 2011, including the submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) by Adamis Pharmaceuticals Corp., the status of Auxilium Pharmaceutical Incorporated's study of...

  • Clinic Roundup.  // BioWorld Today;8/31/2011, Vol. 22 Issue 169, p4 

    The article discusses the first patient enrolled by Adamis Pharmaceuticals Corp. for its Phase I/IIa study of a signal transduction inhibitor, oral anti-androgenic/anti-inflammatory called APC-100 for men who have castrate-resistant prostate cancer.

  • State stem cell research funding agency awards $20 million to UCI, StemCells Inc.  // Biomedical Market Newsletter;8/1/2012, Vol. 21, p1 

    The article presents information on the receiving of grant by StemCells Inc. from stem cell research funding agency for the treatment of cervical spinal cord injury.

  • BioMimetic Raising $40M in Stock Offering.  // Bioworld Week;7/19/2010, Vol. 18 Issue 29, p5 

    The article reports on the stock offering of the biotech company, BioMimetic Therapeutics Inc., in which it has raised 40 million dollars as its net proceeds for the funding of clinical trials and research development projects in the U.S.

  • Clinic Roundup.  // BioWorld Today;4/3/2012, Vol. 23 Issue 64, p7 

    This section offers news briefs on clinical trials. Nektar Therapeutics Inc. has dosed the first subjects in the Phase I trial of a short-acting mu-opioid analgesic candidate. Patient enrollment was completed by Oncolytics Biotech Inc. for the first stage of its Phase III trial of Reolysin in...

  • Clinic Roundup.  // BioWorld Today;8/5/2013, Vol. 24 Issue 148, p3 

    The reports focuses on research by therapeutics developer Stemcells Inc. which examined transplantation of its purified human neural stem cells into patients with Pelizaeus-Merzbacher disease (PMD).

  • Restructuring Roundup.  // BioWorld Today;6/5/2009, Vol. 20 Issue 107, p3 

    The article unveils the plan of StemCells Inc. to close its Stem Cell Sciences facility in Melbourne, Victoria. The closure, according to the company, aims to streamline its operations and reduce its burn rate. The Australian operations of the company will be transferred to its locations in Palo...

  • Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada.  // Biomedical Market Newsletter;11/7/2011, Vol. 21, p164 

    The article reports on the Notice of Allowance received by Adamis Pharmaceuticals Corp. for the technology that constitutes its compound APC-100 for the patent application in Canada. It states that the APC-100 is part of the Phase 1/2a clinical prostate trial at the University of Wisconsin...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics